APP and Alzheimer disease: A combination of early Aβ-PET, 18FDG-PET, and DTI MRI and/or fMRI to detect neurodegeneration, supported by genetic tests of the mutated APP, PSEN1, PSEN2, and APOE4, may be appropriate for preclinical AD diagnosis.